- Company name
- CVS Health
- Sector
- Health care services & pharmacy
- About
- CVS Health has three segments. Health Care Benefits runs Aetna, which sells medical, pharmacy, dental and behavioral health plans, including government plans. Health Services runs the CVS Caremark pharmacy benefit manager and health care delivery services. Pharmacy & Consumer Wellness runs CVS Pharmacy retail stores and infusion services. Total revenues were $108.4 billion in Q3 2026, and Aetna had 26.1 million medical members at September 30, 2026. CVS left the individual exchange business in 2026. David Joyner is Chairman and CEO. On November 4, 2026, CVS said it plans to separate into two public companies in the first half of 2028: a healthcare solutions company with Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health, and CVS Pharmacy with about 9,000 retail pharmacies.
- Thesis
- The market prices CVS for the risk that medical costs and pressure on pharmacy benefits cut its profits again. In Q2 2025, Aetna recorded a $471 million premium deficiency reserve for Group Medicare Advantage, and CVS still warns of elevated cost trends. Caremark keeps giving price improvements to clients, and CVS has an accrual of about $3.4 billion for opioid litigation. In 2026 the recovery plan is working: the medical benefit ratio fell to 91.3% in Q3 2026 from 92.8% a year earlier, and on November 4, 2026 CVS raised its 2026 adjusted EPS guidance to at least $8.20. On the same day, CVS said it plans to separate its retail pharmacy business from Aetna and Caremark in the first half of 2028. For the gap to close, three things must be true. Aetna's margins must keep recovering in 2027, which depends on Medicare Advantage rates and medical cost trends. Caremark must keep its profit as client pricing improves. Debt must keep falling from $60.7 billion at September 30, 2026, and the separation must leave both companies with the solid investment grade ratings that CVS expects. The 2027 guidance, expected with the Q4 2026 report in early February 2027, is the next test, and the details of the separation come over 2027. If these checks pass, the gap can close over the next four to six quarters. The main reason it may not close is a new rise in medical costs, which CVS cannot fully price for in the short term.
- Risks
- Aetna's profit depends on medical costs staying within what it priced. CVS warns of continued elevated cost trends. A new rise in costs, as in 2025, lowers earnings quickly.
Caremark keeps giving pricing improvements to clients, and laws or rules on pharmacy benefit managers can change how they earn money. These changes can lower Health Services profit.
CVS had a remaining accrual of about $3.4 billion for opioid litigation at September 30, 2026. In October 2026, it paid $315 million, which it had accrued, to settle a federal case about opioid and other controlled substance prescriptions. Some states and private plaintiffs are not part of the settlement, and the final cost may be higher.
Fewer Aetna Medicare Advantage members are in plans with 4 stars or higher for 2027: more than 69%, down from more than 81% for 2026. Lower ratings reduce the quality bonus payments in 2028, and Aetna must improve its ratings to get them back.
Total debt was $60.7 billion at September 30, 2026. Large debt limits buybacks and investment until it falls further.
CVS plans to separate its retail pharmacy business in the first half of 2028. The separation needs final board approval, an SEC registration and confirmation that it is tax-free. It will cost money and management time, and the split of the debt between the two companies is not yet known.
- Balance sheet
- Cash: $11.7B
Debt: $60.7B
Net debt: $48.9B
Interest cover: 5.7×
Undrawn credit line: $7.5B, to May 2029
Debt due within 12 months: $3.5B
CVS funds itself mainly with long-term senior notes. At September 30, 2026, long-term debt was $57.22 billion and the current portion was $3.46 billion, for total debt of $60.68 billion, down from $64.57 billion at December 31, 2025. There was no commercial paper outstanding, and the three $2.5 billion back-up credit facilities, which expire in May 2029, 2030 and 2031, were undrawn. Cash and cash equivalents were $11.74 billion, up from $8.45 billion, and about $5.9 billion of it was held by the parent company or nonrestricted subsidiaries. Interest cover is operating income of $12.95 billion divided by interest expense of $2.28 billion for the first nine months of 2026. Cash flow from operations was $15.3 billion in the first nine months of 2026, and CVS raised its 2026 guidance to at least $15.5 billion on November 4, 2026. The remaining accrual for opioid litigation was about $3.4 billion at September 30, 2026. CVS expects both companies after the planned separation in 2028 to have a solid investment grade rating.
As of Sep 30, 2026.
- Checkpoints
- Nov 4, 2026: Q3 2026 earnings: medical costs. Passed. Watch: A stable medical benefit ratio and 2026 adjusted EPS guidance kept or raised pass; a higher medical benefit ratio or a guidance cut fail. Outcome: The medical benefit ratio fell to 91.3% from 92.8% a year earlier, and CVS raised its 2026 adjusted EPS guidance to at least $8.20 from $7.90 to $8.10.
Feb 4, 2027 (estimate): 2027 guidance. Pending. Watch: 2027 guidance for higher adjusted EPS and continued Aetna margin recovery pass; guidance for lower earnings fails.
Q2 2028 (estimate): Separation of CVS Pharmacy. Pending. Watch: A tax-free separation in the first half of 2028 with a solid investment grade rating for both companies passes; a delay, a taxable deal or a rating below investment grade fails.
- Recent events
- Nov 4, 2026: CVS said that it plans to separate into two public companies, in a separation that it intends to be tax-free and expects to complete in the first half of 2028. The healthcare solutions company keeps Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health, with David Joyner as Chairman and CEO. CVS Pharmacy gets about 9,000 pharmacies, mail pharmacy, MinuteClinic and Health100, with Prem Shah as CEO. CVS expects both companies to have a solid investment grade rating.
Nov 4, 2026: CVS reported Q3 2026 results. Total revenues rose 5.4% to $108.4 billion, and adjusted EPS rose to $2.09 from $1.60. The Aetna medical benefit ratio fell to 91.3% from 92.8%. CVS raised its 2026 adjusted EPS guidance to at least $8.20 from $7.90 to $8.10 and its cash flow from operations guidance to at least $15.5 billion from at least $11.5 billion.
Oct 8, 2026: Aetna said that more than 69% of its Medicare Advantage members are in plans with a rating of 4 stars or higher for 2027. For 2026, the figure was more than 81%. The star ratings set the quality bonus payments that Aetna receives in 2028.
Aug 17, 2026: CVS said that Larry Robbins resigned from its board on August 13, 2026, with no disagreement with the company. The board appointed Teresa Heitsenrether, Chief Data & Analytics Officer of JPMorgan Chase, as a director effective November 18, 2026.
Aug 5, 2026: CVS reported Q2 2026 results. Total revenues rose 7.3% to $106.1 billion, and adjusted EPS rose to $2.58 from $1.81. The Aetna medical benefit ratio fell to 87.4% from 89.9%. CVS raised its 2026 adjusted EPS guidance to $7.90 to $8.10 and its cash flow from operations guidance.
May 6, 2026: CVS reported Q1 2026 results. Total revenues were $100.4 billion, and adjusted EPS was $2.57, up from $2.25. It raised its 2026 adjusted EPS guidance to $7.30 to $7.50.